ArticleHypertension research : official journal of the Japanese Society of Hypertension2026
Recombinant zoster vaccine and risk of kidney failure, cardiovascular, and mortality in patients with chronic kidney disease.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individuals with chronic kidney disease are at increased risk for herpes zoster, cardiovascular events, kidney failure, and premature mortality. Although the recombinant zoster vaccine effectively prevents herpes zoster, its broader systemic effects in this population remain unclear. We conducted a retrospective cohort study of adults aged 50 years or older with incident chronic kidney disease using the U.S.-based TriNetX network from 2017 to 2024. A total of 13,218 vaccine recipients were propensity score-matched to 13,218 unvaccinated controls. The primary outcome was a kidney event, defined as progression to end-stage kidney disease or initiation of dialysis. Secondary outcomes included cardiovascular events and all-cause mortality. Cox proportional hazards models were used to estimate hazard ratios, with additional analyses of restricted mean survival time over five years and incidence rate differences. After a median follow-up of 3.0 years (IQR, 1.5-4.9), recombinant zoster vaccination was associated with significantly lower risks of kidney events (hazard ratio, 0.63; 95% CI, 0.57-0.70), cardiovascular events (hazard ratio, 0.74; 95% CI, 0.68-0.80), and all-cause mortality (hazard ratio, 0.51; 95% CI, 0.48-0.54). Greater risk reductions were observed among individuals who completed the two-dose series. These findings suggest that recombinant zoster vaccination in patients with chronic kidney disease is associated with substantial and sustained reductions in kidney disease progression, cardiovascular events, and mortality, supporting a potential role for vaccination in long-term cardiorenal protection.
Indexed as
Identifiers
42665648What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.